share_log
Benzinga ·  Apr 25 07:24
HOOKIPA Pharma Announced Its Final Pivotal Phase 2/3 Trial Design For HB-200 In Combination With Pembrolizumab Based On Alignment With The FDA
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment